Literature DB >> 20522091

Pathologic correlates of dementia in individuals with Lewy body disease.

Joshua A Sonnen1, Nadia Postupna, Eric B Larson, Paul K Crane, Shannon E Rose, Kathleen S Montine, James B Leverenz, Thomas J Montine.   

Abstract

Cognitive impairment and dementia are more common in patients with Parkinson disease (PD) than age-matched controls and appear to become more frequent as PD progresses. However, estimates of dementia in patients with PD have varied widely, likely due in part to differences in case definition, case ascertainment and methodology. First, we review investigations of usual pathologic correlates of dementia in patients with brainstem (b) Lewy Body Disease (LBD) and report our findings from the initial 266 brain autopsies from a population-based study of brain aging and incident dementia. Our results showed that 2.6% of subjects were diagnosed with PD during life but that 20% had bLBD at autopsy. Seventy percent of individuals with bLBD had high level of one or more cerebral pathologic changes significantly associated with dementia: Alzheimer's disease (AD), cerebral (c) LBD or microvascular brain injury (microVBI); these were commonly co-morbid. Next we consider proposed contributors to cognitive impairment and dementia in the approximately 30% of patients with only bLBD, including regionally selective dendritic degeneration of neostriatal medium spiny neurons. Diseases contributing to cognitive impairment and dementia in patients with bLBD are heterogeneous, providing diagnostic challenges as well as multiple opportunities for successful intervention in patients with PD.

Entities:  

Mesh:

Year:  2010        PMID: 20522091      PMCID: PMC2881486          DOI: 10.1111/j.1750-3639.2009.00371.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  42 in total

1.  Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

Authors:  Hulya Apaydin; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Dennis W Dickson
Journal:  Arch Neurol       Date:  2002-01

Review 2.  Alzheimer's disease and Parkinson's disease.

Authors:  Robert L Nussbaum; Christopher E Ellis
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

3.  Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology.

Authors:  U Rüb; K Del Tredici; C Schultz; E Ghebremedhin; R A I de Vos; E Jansen Steur; H Braak
Journal:  Neurobiol Aging       Date:  2002 Mar-Apr       Impact factor: 4.673

4.  Motor impairment in PD: relationship to incident dementia and age.

Authors:  G Levy; M X Tang; L J Cote; E D Louis; B Alfaro; H Mejia; Y Stern; K Marder
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

5.  Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions.

Authors:  V Haroutunian; M Serby; D P Purohit; D P Perl; D Marin; M Lantz; R C Mohs; K L Davis
Journal:  Arch Neurol       Date:  2000-08

6.  Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.

Authors:  J O Rinne; R Portin; H Ruottinen; E Nurmi; J Bergman; M Haaparanta; O Solin
Journal:  Arch Neurol       Date:  2000-04

7.  Dopaminergic modulation of cortical function in patients with Parkinson's disease.

Authors:  Venkata S Mattay; Alessandro Tessitore; Joseph H Callicott; Alessandro Bertolino; Terry E Goldberg; Thomas N Chase; Thomas M Hyde; Daniel R Weinberger
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

Review 8.  Dementia associated with Parkinson's disease.

Authors:  Murat Emre
Journal:  Lancet Neurol       Date:  2003-04       Impact factor: 44.182

9.  Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study.

Authors:  Jennifer Molano; Bradley Boeve; Tanis Ferman; Glenn Smith; Joseph Parisi; Dennis Dickson; David Knopman; Neill Graff-Radford; Yonas Geda; John Lucas; Kejal Kantarci; Maria Shiung; Clifford Jack; Michael Silber; V Shane Pankratz; Ronald Petersen
Journal:  Brain       Date:  2009-11-04       Impact factor: 13.501

10.  Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

Authors:  Iracema Leroi; Jason Brandt; Stephen G Reich; Constantine G Lyketsos; Stephen Grill; Richard Thompson; Laura Marsh
Journal:  Int J Geriatr Psychiatry       Date:  2004-01       Impact factor: 3.485

View more
  13 in total

1.  Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

Authors:  James B Leverenz; G Stennis Watson; Jane Shofer; Cyrus P Zabetian; Jing Zhang; Thomas J Montine
Journal:  Parkinsonism Relat Disord       Date:  2010-11-01       Impact factor: 4.891

Review 2.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

Review 3.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

4.  Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Stephanie Studenski; Kirk A Frey; Nicolaas I Bohnen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-05-26       Impact factor: 6.053

5.  Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.

Authors:  James F Burke; Roger L Albin; Robert A Koeppe; Bruno Giordani; Michael R Kilbourn; Sid Gilman; Kirk A Frey
Journal:  Brain       Date:  2011-05-09       Impact factor: 13.501

6.  Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples.

Authors:  Willa D Brenowitz; C Dirk Keene; Stephen E Hawes; Rebecca A Hubbard; W T Longstreth; Randy L Woltjer; Paul K Crane; Eric B Larson; Walter A Kukull
Journal:  Neurobiol Aging       Date:  2017-01-30       Impact factor: 4.673

7.  Association of Parkinson disease risk loci with mild parkinsonian signs in older persons.

Authors:  Joshua M Shulman; Lei Yu; Aron S Buchman; Denis A Evans; Julie A Schneider; David A Bennett; Philip L De Jager
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

8.  Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.

Authors:  Min Shi; Lu Tang; Jon B Toledo; Carmen Ginghina; Hua Wang; Patrick Aro; Poul H Jensen; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Murray Grossman; Leo McCluskey; Lauren B Elman; David A Wolk; Edward B Lee; Leslie M Shaw; John Q Trojanowski; Jing Zhang
Journal:  Alzheimers Dement       Date:  2018-03-28       Impact factor: 21.566

9.  Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease.

Authors:  Aron S Buchman; Sukriti Nag; Sue E Leurgans; Jared Miller; Veronique G J M VanderHorst; David A Bennett; Julie A Schneider
Journal:  Brain Pathol       Date:  2017-10-27       Impact factor: 6.508

10.  Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies.

Authors:  Aron S Buchman; Lei Yu; Robert S Wilson; Sue E Leurgans; Sukriti Nag; Joshua M Shulman; Lisa L Barnes; Julie A Schneider; David A Bennett
Journal:  Neurology       Date:  2019-03-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.